Commentary
Video
Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
“[EGFR]-targeted drugs emerged, and we saw activity in patients with lung cancer. It wasn’t known for approximately 4 to 6 years later that there were mutations that caused that, but we had a breakthrough, and then we built on that.”
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine, discusses advances in EGFR inhibition throughout the past several decades for patients with lung cancer.
